Enhancement of EPR Effect for Passive Tumor Targeting: Current Status and Future Perspectives
Source abstract
Abstract
The Enhanced Permeability and Retention (EPR) effect is a key mechanism for passive tumor targeting, which involves the selective accumulation of therapeutic nanoparticles in tumors due to their unique vascular characteristics. While previous reviews have explored this phenomenon, the present review offers a comprehensive, multidisciplinary approach, highlighting recent advancements in strategies to enhance the EPR effect, as well as novel insights into the role of tumor microenvironment heterogeneity and the multifaceted approaches to overcome EPR-related challenges. This review provides a detailed analysis of the latest developments in nanocarriers’ design, including size, shape, and surface modifications, as well as cutting-edge multi-stage drug delivery systems. Furthermore, the integration of physical, pharmacological, and combinatory therapies to optimize the EPR effect is also discussed, aiming to improve the clinical translation of nanomedicines. Unlike other reviews, this work emphasizes the dynamic interaction between the tumor microenvironment and the vascular network, which remains underexplored in the current literature. In addition, specific clinical trials’ outcomes are highlighted and future directions to address existing limitations are proposed, offering a clearer roadmap regarding clinical applications in cancer therapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Electron Spin Resonance Studies · Lanthanide and Transition Metal Complexes · Metal complexes synthesis and properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Laboratory of Biology, Department of Basic Medical Sciences, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Laboratory of General Chemistry, School of Chemical Engineering, National Technical University of Athens, Zografou Campus, 15772 Athens, Greece
Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece
References (100+)
Show source-provided references
1. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F ↗
2. Targeting endothelial permeability in the EPR effect10.1016/j.jconrel.2023.07.039 ↗
3. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives10.1016/j.addr.2022.114614 ↗
4. Role of angiogenesis in tumor growth and metastasis10.1053/sonc.2002.37263 ↗
5. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation10.1016/j.jconrel.2022.03.043 ↗
6. Wu, J. (2021). The enhanced permeability and retention (EPR) effect: The significance of the concept and methods to enhance its application. J. Pers. Med., 11.10.3390/jpm11080771 ↗
7. Bae, Y., Mrsny, R., and Park, K. (2013). The EPR Effect in Cancer Therapy. Cancer Targeted Drug Delivery. Cancer Targeted Drug Delivery, Springer.10.1007/978-1-4614-7876-8 ↗
8. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect10.1016/j.addr.2010.04.009 ↗
9. Perspectives on the past, present, and future of cancer nanomedicine10.1016/j.addr.2018.05.008 ↗
10. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
11. Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers10.1200/JCO.2012.46.3653 ↗
12. Nanocarriers as an emerging platform for cancer therapy10.1038/nnano.2007.387 ↗
13. Shape effects of filaments versus spherical particles in flow and drug delivery10.1038/nnano.2007.70 ↗
14. Size-tunable strategies for a tumor targeted drug delivery system10.1021/acscentsci.9b01139 ↗
15. Drug resistance and the solid tumor microenvironment10.1093/jnci/djm135 ↗
16. Design considerations for nanotherapeutics in oncology
17. Applications of inorganic nanoparticles as therapeutic agents10.1088/0957-4484/25/1/012001 ↗
18. Antiangiogenic properties of gold nanoparticles10.1158/1078-0432.CCR-04-2482 ↗
19. Recent development of metal nanoparticles for angiogenesis study and their therapeutic applications10.1021/acsabm.9b00587 ↗
20. Size-dependent EPR effect of polymeric nanoparticles on tumor targeting10.1002/adhm.201901223 ↗
21. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect10.1016/j.addr.2010.10.008 ↗
22. Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics10.7150/thno.27828 ↗
23. Biodegradable polymers for targeted delivery of anti-cancer drugs10.1517/17425247.2016.1156671 ↗
24. García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., and López-Romero, J.M. (2019). Lipid-based nanoparticles: Application and recent advances in cancer treatment. Nanomaterials, 9.10.3390/nano9040638 ↗
25. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles10.1016/j.addr.2007.04.008 ↗
26. Codelivery of doxorubicin and curcumin with lipid nanoparticles results in improved efficacy of chemotherapy in liver cancer
27. Lipid nanoparticles for chemotherapeutic applications: Strategies to improve anticancer efficacy10.1517/17425247.2012.685933 ↗
28. Hybrid nanoparticles for detection and treatment of cancer10.1002/adma.201200653 ↗
29. EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles10.7150/thno.37543 ↗
30. Tumor microenvironment and nanotherapeutics
31. Tumor microenvironment: Recent advances in various cancer treatments
32. The tumor microenvironment10.1016/j.cub.2020.06.081 ↗
33. Tumor microenvironment as a therapeutic target in cancer10.1016/j.pharmthera.2020.107753 ↗
34. Tumour microenvironment responsive nanoconstructs for cancer theranostic10.1016/j.nantod.2019.03.007 ↗
35. The tumor microenvironment10.1016/j.suronc.2011.09.001 ↗
36. Arneth, B. (2020). Tumor microenvironment. Medicina, 56.10.3390/medicina56010015 ↗
37. Immunological hallmarks of stromal cells in the tumour microenvironment10.1038/nri3902 ↗
38. Tumor microenvironment components: Allies of cancer progression
39. Influence of tumour micro-environment heterogeneity on therapeutic response10.1038/nature12626 ↗
40. Roma-Rodrigues, C., Mendes, R., Baptista, P.V., and Fernandes, A.R. (2019). Targeting tumor microenvironment for cancer therapy. Int. J. Mol. Sci., 20.10.3390/ijms20040840 ↗
41. Tumor microenvironment and therapeutic response10.1016/j.canlet.2016.01.043 ↗
42. Targeting the tumour stroma to improve cancer therapy10.1038/s41571-018-0007-1 ↗
43. Nikolopoulou, P.A., Koufaki, M.A., and Kostourou, V. (2021). The adhesome network: Key components shaping the tumour stroma. Cancers, 13.10.3390/cancers13030525 ↗
44. The hypoxic tumour microenvironment10.1038/s41389-017-0011-9 ↗
45. An overview of the tumor microenvironment, from cells to complex networks10.3892/etm.2020.9528 ↗
46. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy10.1016/j.canlet.2019.11.009 ↗
47. Mesenchymal stem cells in the tumor microenvironment
48. Pericytes in the tumor microenvironment10.1016/j.canlet.2023.216074 ↗
49. Chemokines and cancer10.1002/ijc.22024 ↗
50. Growth factors and cancer
51. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses10.1038/s41587-023-01957-8 ↗
52. Walker, C., Mojares, E., and Del Río Hernández, A. (2018). Role of extracellular matrix in development and cancer progression. Int. J. Mol. Sci., 19.10.3390/ijms19103028 ↗
53. Gap junctions: Basic structure and function10.1038/sj.jid.5700770 ↗
54. Communication through gap junctions in the endothelium10.1016/bs.apha.2016.04.004 ↗
55. Beckmann, A., Hainz, N., Tschernig, T., and Meier, C. (2019). Facets of communication: Gap junction ultrastructure and function in cancer stem cells and tumor cells. Cancers, 11.10.3390/cancers11030288 ↗
56. Ma, F., Zhang, S., Song, L., Wang, B., Wei, L., and Zhang, F. (2021). Applications and analytical tools of cell communication based on ligand-receptor interactions at single cell level. Cell Biosci., 11.10.1186/s13578-021-00635-z ↗
57. Microenvironmental regulation of tumour angiogenesis10.1038/nrc.2017.51 ↗
58. Anderson, J.M., and Van Itallie, C.M. (2009). Physiology and function of the tight junction. Cold Spring Harb. Perspect. Biol., 1.10.1101/cshperspect.a002584 ↗
59. Claudin-based barrier in simple and stratified cellular sheets10.1016/S0955-0674(02)00362-9 ↗
60. Loss of tight junction barrier function and its role in cancer metastasis10.1016/j.bbamem.2008.11.005 ↗
61. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways
62. Cell communication by tunneling nanotubes: Implications in disease and therapeutic applications10.1002/jcp.27072 ↗
63. Tunneling nanotubes and related structures: Molecular mechanisms of formation and function10.1042/BCJ20210077 ↗
64. The art of cellular communication: Tunneling nanotubes bridge the divide10.1007/s00418-008-0412-0 ↗
65. Roehlecke, C., and Schmidt, M.H.H. (2020). Tunneling nanotubes and tumor microtubes in cancer. Cancers, 12.10.3390/cancers12040857 ↗
66. Extracellular vesicles and oncogenic signaling10.1002/1878-0261.12855 ↗
67. Metabolic and signaling functions of cancer cell-derived extracellular vesicles10.1016/bs.ircmb.2016.04.004 ↗
68. Signaling by extracellular vesicles advances cancer hallmarks10.1016/j.trecan.2015.12.005 ↗
69. Targeting cytokine and chemokine signaling pathways for cancer therapy10.1038/s41392-024-01868-3 ↗
70. Chemokines in cancer10.1016/S1359-6101(01)00033-8 ↗
71. Chemokine receptor signaling and the hallmarks of cancer10.1016/bs.ircmb.2016.09.011 ↗
72. Subhan, M.A., Yalamarty, S.S.K., Filipczak, N., Parveen, F., and Torchilin, V.P. (2021). Recent advances in tumor targeting via EPR effect for cancer treatment. J. Pers. Med., 11.10.3390/jpm11060571 ↗
73. Extracellular matrix structure10.1016/j.addr.2015.11.001 ↗
74. Heterogeneity of the tumor vasculature10.1055/s-0030-1253454 ↗
75. Vascular permeability-the essentials10.3109/03009734.2015.1064501 ↗
76. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents10.1016/j.ctrv.2010.05.001 ↗
77. Tumor angiogenesis: Insights and innovations10.1155/2010/132641 ↗
78. Vasculogenensis, angiogenesis and special features of tumor blood vessels10.2741/3796 ↗
79. Basic and therapeutic aspects of angiogenesis updated10.1161/CIRCRESAHA.120.316851 ↗
80. Basic and therapeutic aspects of angiogenesis10.1016/j.cell.2011.08.039 ↗
81. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets10.1007/s10456-017-9562-9 ↗
82. Nanodrug delivery: Is the enhanced permeability and retention effect sufficient for curing cancer?10.1021/acs.bioconjchem.6b00437 ↗
83. Implications of cellular immaturity in necrosis and microvascularization in glioblastomas IDH-wild-type10.3390/clinpract12060108 ↗
84. Heterogeneity of the tumor vasculature: The need for new tumor blood vessel type-specific targets10.1007/s10585-012-9500-6 ↗
85. Teicher, B.A., and Ellis, L.M. (2008). Tumor blood vessels: Structure, function and classification. Antiangiogenic Agents in Cancer Therapy. Cancer Drug Discovery and Development, Humana Press.10.1007/978-1-59745-184-0 ↗
86. Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises10.1016/j.devcel.2011.07.001 ↗
87. Tumor angiogenesis and therapy10.1016/S0753-3322(05)80070-8 ↗
88. The endothelium and its role in regulating vascular tone10.2174/1874192401004010302 ↗
89. Tumor angiogenesis10.1016/S0065-230X(08)60946-X ↗
90. Tumor angiogenesis: Molecular pathways and therapeutic targets10.1038/nm.2537 ↗
91. The role of microenvironment in tumor angiogenesis10.1186/s13046-020-01709-5 ↗
92. Tumor angiogenesis: Current challenges and therapeutic opportunities10.1016/j.ctarc.2021.100422 ↗
93. Tumor angiogenesis10.1046/j.1087-0024.2000.00003.x ↗
94. Molecular mechanisms of tumor angiogenesis and tumor progression10.1023/A:1006414621286 ↗
95. Vascular endothelium in cancer10.1007/s00441-008-0707-4 ↗
96. Tumor angiogenesis revisited: Regulators and clinical implications10.1002/med.21452 ↗
97. Tumor angiogenesis: Causes, consequences, challenges and opportunities10.1007/s00018-019-03351-7 ↗
98. Tumor Angiogenesis10.1056/NEJMra0706596 ↗
99. Vascular permeability changes involved in tumor metastasis10.1016/j.canlet.2013.03.005 ↗
100. Azzi, S., Hebda, J.K., and Gavard, J. (2013). Vascular permeability and drug delivery in cancers. Front. Oncol., 3.10.3389/fonc.2013.00211 ↗